Pharmacokinetic studies ask how the body handles an intervention. They do not, by themselves, establish long-term effectiveness or safety in every patient with organ disease. Primary study
Two studies in one report
A 2026 report contains two separate single-exposure studies. The renal study included 33 participants: 14 with normal function, seven with mild impairment, seven with moderate impairment and five with severe impairment. The hepatic study included 32: 14, seven, seven and four in the corresponding categories. The primary total-exposure assessment extended to day 36 in the renal study and day 39 in the hepatic study.
The authors found no consistent clinically relevant pattern in exposure across impairment categories, within the limitations of small samples. The severe-renal group illustrates the uncertainty: its estimated mean total-exposure ratio relative to normal renal function was 1.21, with a 90% confidence interval of 0.87–1.68. A point estimate near one and a broad interval are not evidence of exact equivalence.
The report recorded 21 treatment-emergent events in 11 renal-study participants and 16 in nine hepatic-study participants, without serious treatment-emergent events, withdrawals caused by such events or deaths. Those are short-study observations, not evidence excluding uncommon harms after repeated exposure. The title's broad language about organ impairment needs to be read alongside the single-exposure methods and small groups.
Our appraisal: similarity needs uncertainty
Similar point estimates do not imply identical exposure. Confidence intervals show the range of differences compatible with the data. Any conclusion about clinical relevance should be tied to a justified exposure boundary rather than the absence of a conventional significance test alone.
A single-dose experiment also differs from repeated use. Accumulation, evolving illness, co-medication changes, and uncommon adverse effects may require other evidence. A short observation period cannot rule out rare or delayed harms.
Renal and hepatic impairment are separate study populations, not interchangeable categories of “poor clearance.” Their classifications and exclusion criteria should remain visible. Results from selected volunteers with stable impairment may not cover acute organ failure or every dialysis situation.
The authors' development-oriented dosing interpretation should not become a personal dosing instruction on a research website. Clinical use depends on the complete evidence base and applicable product guidance, not one isolated paper.
Full review should examine matching, group definitions, exposure intervals, assay methods, protein-binding considerations where relevant, and safety follow-up. This report provides specific pharmacokinetic evidence, not a guarantee that cagrilintide is risk-free in renal or hepatic disease.
Frequently asked questions
Did one report include two separate studies?
Yes.
Was repeated long-term administration studied here?
No; these were single-dose studies.
Were severe-impairment groups large?
No.
Do similar averages establish identical exposure?
No.
Does short-term tolerability exclude rare harms?
No.
Can this page provide an individual dose adjustment?
No.
What should remain attached to the conclusion?
The selected populations, single-dose design, exposure uncertainty, and limited safety window.